Leadership team
(In order of appearance in photo, left to right)

Kevin A. Lobo
Chairman and Chief Executive Officer


Glenn S. Boehnlein
Vice President, Chief Financial Officer


Robert S. Fletcher
Vice President, Chief Legal Officer


Viju S. Menon
Group President, Global Quality and Operations


Yin C. Becker
Vice President, Communications, Public Affairs and Corporate Marketing

Timothy J. Scannell
President and Chief Operating Officer


J. Andrew Pierce
Group President, MedSurg and Neurotechnology


Spencer S. Stiles
Group President, Orthopaedics and Spine


M. Kathryn (Katy) Fink
Vice President, Chief Human Resources Officer


Katherine A. Owen
Vice President, Strategy and Investor Relations


Division Presidents



Xavier M. C. Berling
Trauma & Extremities


Dylan B. Crotty


Brent W. Ladd


Eric D. Major


Mark H. Paul


Donald E. Payerle
Joint Replacement


Bradford L. Saar

Brian J. White
Sustainability Solutions


Maurice Ben-Mayor
South Pacific


Silvia L. F. Braga
Latin America


Dragana Bunjevac
Eastern Europe, Middle East, Africa


Scott A. MacNair


Graham A. McLean
Asia Pacific


Hiroyuki Saeki


Stuart A. J. Silk
Europe, Middle East, Africa, Latin America, Canada


Other Officers

Dean H. Bergy
Vice President, Corporate Secretary


William E. Berry, Jr.
Vice President, Corporate Controller


Jeanne M. Blondia
Vice President, Finance and Treasurer


Irene B. Corbe
Vice President, Internal Audit


William J. Cymbaluk
Vice President, Corporate Regulatory Affairs and Quality Assurance

David G. Furgason
Vice President, Tax


Jody K. Powell
Vice President, Global Regulatory Affairs and Quality Assurance

Bronwen R. Taylor
Vice President, Compliance and Risk Management

Board of Directors
(In order of appearance in photo, left to right)

Louise L. Francesconi ‡ §

Rajeev Suri **

Ronda E. Stryker §

Mary K. Brainerd **

Andrew K. Silvernail **

Allan C. Golston † **

Srikant M. Datar, Ph.D. ‡ §

Roch Doliveux, D.V.M. ‡ §

Sherilyn S. McCoy ‡ §

Kevin A. Lobo *

* Chairman of the Board
† Lead Independent Director
** Audit Committee
‡ Compensation Committee
§ Governance and Nominating Committee

Chairman Emeritus
John W. Brown
Former Chairman, President and Chief Executive Officer


Director Emeritus
Howard E. Cox, Jr.


With appreciation

We want to express our gratitude and appreciation to Louise Francesconi who has served as a director on our board since 2006. Louise has made strong contributions to our strategy and growth during her 14 years on our board and successfully hired many new board members as chair of the governance and nominating committee since 2007. We sincerely thank Louise for her dedication and service.


Louise L. Francesconi

Louise L. Francesconi

Additional information

Independent registered public accounting firm

Ernst & Young LLP
Grand Rapids, Michigan

Transfer agent and registrar

American Stock Transfer & Trust Company, LLC
New York, New York

Shareholders needing information regarding their certificates or dividends should contact:

American Stock Transfer & Trust Company, LLC
Operations Center
6201 15th Avenue
New York, New York 11219
800 937 5449

Investor contact

Katherine A. Owen
Vice President, Strategy and Investor Relations

Media contact

Yin C. Becker
Vice President, Communications, Public Affairs and Corporate Marketing

Business development contact

Bryant S. Zanko
Vice President, Business Development

Annual meeting

The virtual Annual Meeting of Shareholders of Stryker Corporation will be held on Tuesday, May 5, 2020, at 2:00 p.m. ET. 

Access the meeting online at: www.virtualshareholdermeeting.com/SYK2020 

Or by phone, listen only:
U.S. (toll free): 1-877-328-2502
International: 1-412-317-5419

Stock listing

The company’s common stock is traded on the New York Stock Exchange under the symbol SYK.

Form 10-K

The company files an Annual Report on Form 10-K with the Securities and Exchange Commission. Shareholders may view the 2019 report at www.stryker.com or www.sec.gov

Forward-looking statements

This Annual Review contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: the failure to satisfy any of the closing conditions to the acquisition of Wright Medical, including the receipt of any required regulatory clearances (and the risk that such clearances may result in the imposition of conditions that could adversely affect the expected benefits of the transaction); delays in consummating the acquisition of Wright; unexpected liabilities, costs, charges or expenses in connection with the acquisition of Wright; the effects of the proposed Wright transaction (or the announcement thereof) on the parties’ relationships with employees, customers, other business partners or governmental entities; the impact of the coronavirus (COVID-19); weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products, including Wright products; potential supply disruptions; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to recall-related matters; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; costs to comply with medical device regulations; changes in financial markets; changes in the competitive environment; our ability to integrate and realize the anticipated benefits of acquisitions in full or at all or within the expected timeframes, including the acquisition of Wright; and our ability to realize anticipated cost savings. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Our Annual Review contains many of the valuable trademarks owned and/or used by Stryker and our subsidiaries and affiliates in the U.S. and internationally to distinguish products and services of outstanding quality. All other trademarks featured herein are the property of their respective owners. 

Products may not be available in all markets. Product availability is subject to the regulatory and/or medical practices in individual markets. 

This document is governed solely by applicable U.S. laws and governmental regulations.

Design, video and portrait photography by Addison  www.addison.com

Download the 2019 Annual Review PDF